Trials / Completed
CompletedNCT04519944
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - German Non-interventional Study (ENCOURAGE-AF)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 666 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to gain real-world clinical data on the peri- and post-procedural usage of anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation (NVAF) undergoing successful percutaneous coronary intervention (PCI) treated with edoxaban.
Detailed description
The study will assess real-world evidence data of anticoagulation and antiplatelet therapy in patients with NVAF undergoing PCI treated with edoxaban. The observation period will start 4 to 72 hours after removal of the guiding catheter of successful PCI in a hospital and ends 1 year after procedure. Follow-up telephone calls will take place approximately 1 month and 1 year after PCI. Real-world data of effectiveness of edoxaban and antiplatelet therapy, clinical events of interests, safety and quality of life (QoL) data of edoxaban will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Edoxaban | This is an observational, prospective study; no treatment will be administered. |
Timeline
- Start date
- 2020-06-30
- Primary completion
- 2023-07-06
- Completion
- 2023-07-06
- First posted
- 2020-08-20
- Last updated
- 2023-08-02
Locations
66 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04519944. Inclusion in this directory is not an endorsement.